Lansoprazol Krka

Lansoprazole, the active ingredient in Lansoprazol Krka, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal conditions such as reflux disease and ulcers.

GNH USA supplies Lansoprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through rigorous testing and adheres to global regulatory standards for safe distribution across all markets.

Lansoprazole is used to treat acid‑related disorders by decreasing gastric acid secretion.

- Gastroesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. - Erosive esophagitis: promotes healing of inflamed esophageal lining. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence. - Helicobacter pylori eradication regimens: enhances effectiveness of antibiotic therapy by suppressing acid.

Lansoprazole may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild headache reported in clinical use. - Diarrhea: loose stools occurring during therapy. - Nausea: transient feeling of queasiness. - Abdominal pain: mild stomach discomfort. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Clostridioides difficile infection: persistent diarrhea with abdominal pain. - Low magnesium levels: muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

Before initiating Lansoprazole therapy, consider the following precautions to ensure safe use.

- Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic status: monitor for accumulation in liver disease. - Review concomitant medications: potential interactions may require monitoring. - Use the lowest effective dose: limit duration to the shortest period necessary. - Pregnancy and lactation: discuss risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and light.

Lansoprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): reduced absorption and efficacy. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma levels. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Digoxin: higher serum concentrations may occur. - Methotrexate: reduced renal clearance, monitor for toxicity. - Mycophenolate mofetil: decreased exposure, adjust dose if needed.